The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Vincristine (V), dactinomycin (A), and lower doses of cyclophosphamide (C) with or without radiation therapy for patients with newly diagnosed low-risk embryonal rhabdomyosarcoma (ERMS): A report from the Children’s Oncology Group (COG).
David Walterhouse
No relevant relationships to disclose
Alberto S. Pappo
No relevant relationships to disclose
Jane L Meza
No relevant relationships to disclose
John C. Breneman
No relevant relationships to disclose
Andrea Anita Hayes-Jordan
No relevant relationships to disclose
David Parham
No relevant relationships to disclose
Timothy P Cripe
No relevant relationships to disclose
William H. Meyer
Research Funding - Children's Oncology Group
Douglas S. Hawkins
Research Funding - Children's Oncology Group